Pharsight

Sivextro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(3 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(4 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(5 years from now)

Sivextro is owned by Cubist Pharms Llc.

Sivextro contains Tedizolid Phosphate.

Sivextro has a total of 7 drug patents out of which 0 drug patents have expired.

Sivextro was authorised for market use on 20 June, 2014.

Sivextro is available in powder;intravenous, tablet;oral dosage forms.

Sivextro can be used as method of treating bacterial infections, method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria.

Drug patent challenges can be filed against Sivextro from 21 June, 2023.

The generics of Sivextro are possible to be released after 31 December, 2030.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 20, 2019
Generating Antibiotic Incentives Now(GAIN) Jun 20, 2024
New Patient Population(NPP) Jun 19, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: 21 June, 2023

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER;INTRAVENOUS; TABLET;ORAL

More Information on Dosage

SIVEXTRO family patents

Family Patents